Arch Biopartners Stock Return On Equity
| ARCH Stock | CAD 1.77 0.05 2.91% |
Arch Biopartners fundamentals help investors to digest information that contributes to Arch Biopartners' financial success or failures. It also enables traders to predict the movement of Arch Stock. The fundamental analysis module provides a way to measure Arch Biopartners' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Arch Biopartners stock.
| Last Reported | Projected for Next Year | ||
| Return On Equity | 13.46 | 14.13 |
Arch | Return On Equity |
Arch Biopartners Company Return On Equity Analysis
Arch Biopartners' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Arch Biopartners Return On Equity | 14.13 |
Most of Arch Biopartners' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Arch Biopartners is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Arch Return On Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for Arch Biopartners is extremely important. It helps to project a fair market value of Arch Stock properly, considering its historical fundamentals such as Return On Equity. Since Arch Biopartners' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Arch Biopartners' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Arch Biopartners' interrelated accounts and indicators.
Click cells to compare fundamentals
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Arch Total Stockholder Equity
Total Stockholder Equity |
|
Arch Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Arch Biopartners' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Arch Biopartners could also be used in its relative valuation, which is a method of valuing Arch Biopartners by comparing valuation metrics of similar companies.Arch Biopartners is currently under evaluation in return on equity category among its peers.
Arch Biopartners Current Valuation Drivers
We derive many important indicators used in calculating different scores of Arch Biopartners from analyzing Arch Biopartners' financial statements. These drivers represent accounts that assess Arch Biopartners' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Arch Biopartners' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 82.1M | 104.9M | 187.1M | 6.8M | 6.1M | 5.8M | |
| Enterprise Value | 84.8M | 109.6M | 191.0M | 8.5M | 7.6M | 7.2M |
Arch Fundamentals
| Return On Asset | -0.81 | ||||
| Profit Margin | (1.86) % | ||||
| Operating Margin | (1.39) % | ||||
| Current Valuation | 119.89 M | ||||
| Shares Outstanding | 64.94 M | ||||
| Shares Owned By Insiders | 19.86 % | ||||
| Number Of Shares Shorted | 3.97 K | ||||
| Price To Sales | 83.08 X | ||||
| Revenue | 1.98 M | ||||
| Gross Profit | (502.88 K) | ||||
| EBITDA | (5.24 M) | ||||
| Net Income | (3.33 M) | ||||
| Cash And Equivalents | 72.82 K | ||||
| Total Debt | 5.02 M | ||||
| Current Ratio | 0.32 X | ||||
| Book Value Per Share | (0.10) X | ||||
| Cash Flow From Operations | (234.07 K) | ||||
| Short Ratio | 0.29 X | ||||
| Earnings Per Share | (0.03) X | ||||
| Beta | 1.39 | ||||
| Market Capitalization | 129.88 M | ||||
| Total Asset | 1.17 M | ||||
| Retained Earnings | (28.05 M) | ||||
| Working Capital | (4.81 M) | ||||
| Net Asset | 1.17 M |
About Arch Biopartners Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Arch Biopartners's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arch Biopartners using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arch Biopartners based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arch Stock Analysis
When running Arch Biopartners' price analysis, check to measure Arch Biopartners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arch Biopartners is operating at the current time. Most of Arch Biopartners' value examination focuses on studying past and present price action to predict the probability of Arch Biopartners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arch Biopartners' price. Additionally, you may evaluate how the addition of Arch Biopartners to your portfolios can decrease your overall portfolio volatility.